T2 Biosystems CS (TTOO)

$0.08 -0.06 (-41.49%)
Market Cap 4.09M
Revenue (ttm) 7.19M
Net Income (ttm) -50.08M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -696.52%
Debt to Equity Ratio 0.00
Volume 4,010,500
Avg Vol 1,494,488
Day's Range N/A - N/A
Shares Out 21.04M
Stochastic %K 5%
Beta 0.35
Analysts Hold
Price Target $5.00

Company Profile

T2 Biosystems, Inc. engages in the development and commercialization of medical diagnostic products for critical unmet needs in the healthcare. Its products include T2Dx instrument, T2Candida panel, and T2Bacteria panel. The company was incorporated in 2006 and is based in Lexington, Massachusetts.

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 781 761 4646
Address:
101 Hartwell Avenue, Lexington, United States
Vince_2026
Vince_2026 Mar. 12 at 5:03 PM
$TTOO well that was a disappointment. Only blood culture topics discussed? There is AI info online connecting Dr Hou with T2MR technology in a positive light. AI reply.... Dr. Hou has been a featured expert discussing T2MR as a potential "sepsis breakthrough." In clinical circles, she has addressed the challenge of "Technology ahead of the budget," evaluating how hospitals can justify the cost of T2MR by measuring its impact on patient survival and antibiotic stewardship. yet no T2MR info discussed today in Dr Hou presentation...
0 · Reply
Vince_2026
Vince_2026 Mar. 12 at 4:19 PM
$TTOO Dr Hoa quick diagnostic advocate w/ congress 12:20
0 · Reply
Vince_2026
Vince_2026 Mar. 12 at 3:59 PM
$TTOO starting now
0 · Reply
LicketySplitz03
LicketySplitz03 Mar. 12 at 2:16 PM
$TTOO ⏰🔥💥💰💰💰💰💰💰💰💰
0 · Reply
LicketySplitz03
LicketySplitz03 Mar. 11 at 11:23 PM
$TTOO ⏰💰💰💰💰💰💰💰💰
0 · Reply
GatorYoYo
GatorYoYo Mar. 11 at 4:38 PM
$TTOO Stalking....
2 · Reply
Vince_2026
Vince_2026 Mar. 11 at 1:58 PM
$TTOO starts today at 10 am quick overview of todays speakers Steven Simpson, MD Day One speaker BARDA influence comes through BARDA (Biomedical Advanced Research and Development Authority)— focuses on MDW White Blood Cell testing Ruth Carrico, PhD One speaker serves as the Infection Prevention Architect in the sepsis diagnostic network Hudson Garrett PhD, Day One speaker is the "Safety and Systems Architect" of the sepsis network Vitaly Herasevich, MD Day One Speaker Data Architect Edward Septimus, MD, Day one speaker "Bridge Builder" of the sepsis world.focuses on Stewardship Synergy Dr. Green—an Associate Professor of Pathology and Cell Biology at Columbia University—focuses on the "wet lab" technologies that provide the actual answers."Faster Together: Collaborative Models for Turning Sepsis Diagnosis into Action." https://learn.sepsis.org/sepsis-alliance-symposium-diagnostics-stewardship
3 · Reply
Vince_2026
Vince_2026 Mar. 11 at 12:49 PM
$TTOO AI info DD req'd. Day 2 Symposium speaker. Gemini said Dr. Cindy Hou is a pivotal figure in the intersection of infectious disease, sepsis research, and clinical implementation. At Jefferson Health – New Jersey, she serves as the Infection Control Officer and Medical Director of Research, where she oversees the evaluation and adoption of advanced diagnostic tools. Her connection to T2MR (T2 Magnetic Resonance) technology is primarily through her leadership in sepsis advocacy and her research into antimicrobial stewardship. Dr. Hou’s most significant recent connection to T2MR-style diagnostics is her collaboration with Dr. Michael McCurdy on the 2025 Sepsis Alliance Collaborative Statement. She served as a key panelist for the report titled "Challenges Facing Developers of Diagnostic Tests for Sepsis." This paper critiques the "Gold Standard" fallacy—the regulatory hurdle where high-sensitivity tests like T2MR are unfairly compared to traditional, less sensitive blood cultures.
2 · Reply
Vince_2026
Vince_2026 Mar. 11 at 12:04 PM
$TTOO Symposium Day 2 speaker 1:30pm Dr. McCurdy’s Gemini said The 2025 report by Dr. Michael T. McCurdy and the Infection Management and Sepsis Collaborative Community (IMSCC) identifies a central paradox: we have "Space Age" technology like T2MR and FcMBL, but we are trying to prove they work using "Stone Age" benchmarks. Dr. McCurdy’s work highlights several specific hurdles that keep these life-saving DARPA-style innovations in the "valley of death" between the lab and the hospital bed. The Defense Advanced Research Projects Agency (DARPA) is essentially the "mad scientist" wing of the U.S. Department of Defense. FDA and regulators still use blood cultures for comparison. The Hurdle: When a fast DARPA-funded test (like T2MR) finds a pathogen that a culture missed, regulators often view it as a "false positive" rather than a "superior find." This makes it incredibly difficult to prove the diagnostic accuracy required for full clinical adoption.
1 · Reply
Vince_2026
Vince_2026 Mar. 11 at 2:40 AM
$TTOO IMO seeing the Beckman Coulter / Innovaccer (AI) partnership is not an acquisition saves Danaher from reaching into its' dry powder....hmmm 🤔 Rainer Blair’s comments at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, Danaher CEO Rainer Blair provided a critical update on Cepheid’s trajectory strategy for Danaher, even while they digest the Masimo acquisition. The key takeaway is the sheer scale of their remaining "dry powder"—Blair’s confirmation of $20 billion+ Just saying glad Danaher is not depleting its dry powder to get into an AI partnership...
0 · Reply
Latest News on TTOO
No data available.
Vince_2026
Vince_2026 Mar. 12 at 5:03 PM
$TTOO well that was a disappointment. Only blood culture topics discussed? There is AI info online connecting Dr Hou with T2MR technology in a positive light. AI reply.... Dr. Hou has been a featured expert discussing T2MR as a potential "sepsis breakthrough." In clinical circles, she has addressed the challenge of "Technology ahead of the budget," evaluating how hospitals can justify the cost of T2MR by measuring its impact on patient survival and antibiotic stewardship. yet no T2MR info discussed today in Dr Hou presentation...
0 · Reply
Vince_2026
Vince_2026 Mar. 12 at 4:19 PM
$TTOO Dr Hoa quick diagnostic advocate w/ congress 12:20
0 · Reply
Vince_2026
Vince_2026 Mar. 12 at 3:59 PM
$TTOO starting now
0 · Reply
LicketySplitz03
LicketySplitz03 Mar. 12 at 2:16 PM
$TTOO ⏰🔥💥💰💰💰💰💰💰💰💰
0 · Reply
LicketySplitz03
LicketySplitz03 Mar. 11 at 11:23 PM
$TTOO ⏰💰💰💰💰💰💰💰💰
0 · Reply
GatorYoYo
GatorYoYo Mar. 11 at 4:38 PM
$TTOO Stalking....
2 · Reply
Vince_2026
Vince_2026 Mar. 11 at 1:58 PM
$TTOO starts today at 10 am quick overview of todays speakers Steven Simpson, MD Day One speaker BARDA influence comes through BARDA (Biomedical Advanced Research and Development Authority)— focuses on MDW White Blood Cell testing Ruth Carrico, PhD One speaker serves as the Infection Prevention Architect in the sepsis diagnostic network Hudson Garrett PhD, Day One speaker is the "Safety and Systems Architect" of the sepsis network Vitaly Herasevich, MD Day One Speaker Data Architect Edward Septimus, MD, Day one speaker "Bridge Builder" of the sepsis world.focuses on Stewardship Synergy Dr. Green—an Associate Professor of Pathology and Cell Biology at Columbia University—focuses on the "wet lab" technologies that provide the actual answers."Faster Together: Collaborative Models for Turning Sepsis Diagnosis into Action." https://learn.sepsis.org/sepsis-alliance-symposium-diagnostics-stewardship
3 · Reply
Vince_2026
Vince_2026 Mar. 11 at 12:49 PM
$TTOO AI info DD req'd. Day 2 Symposium speaker. Gemini said Dr. Cindy Hou is a pivotal figure in the intersection of infectious disease, sepsis research, and clinical implementation. At Jefferson Health – New Jersey, she serves as the Infection Control Officer and Medical Director of Research, where she oversees the evaluation and adoption of advanced diagnostic tools. Her connection to T2MR (T2 Magnetic Resonance) technology is primarily through her leadership in sepsis advocacy and her research into antimicrobial stewardship. Dr. Hou’s most significant recent connection to T2MR-style diagnostics is her collaboration with Dr. Michael McCurdy on the 2025 Sepsis Alliance Collaborative Statement. She served as a key panelist for the report titled "Challenges Facing Developers of Diagnostic Tests for Sepsis." This paper critiques the "Gold Standard" fallacy—the regulatory hurdle where high-sensitivity tests like T2MR are unfairly compared to traditional, less sensitive blood cultures.
2 · Reply
Vince_2026
Vince_2026 Mar. 11 at 12:04 PM
$TTOO Symposium Day 2 speaker 1:30pm Dr. McCurdy’s Gemini said The 2025 report by Dr. Michael T. McCurdy and the Infection Management and Sepsis Collaborative Community (IMSCC) identifies a central paradox: we have "Space Age" technology like T2MR and FcMBL, but we are trying to prove they work using "Stone Age" benchmarks. Dr. McCurdy’s work highlights several specific hurdles that keep these life-saving DARPA-style innovations in the "valley of death" between the lab and the hospital bed. The Defense Advanced Research Projects Agency (DARPA) is essentially the "mad scientist" wing of the U.S. Department of Defense. FDA and regulators still use blood cultures for comparison. The Hurdle: When a fast DARPA-funded test (like T2MR) finds a pathogen that a culture missed, regulators often view it as a "false positive" rather than a "superior find." This makes it incredibly difficult to prove the diagnostic accuracy required for full clinical adoption.
1 · Reply
Vince_2026
Vince_2026 Mar. 11 at 2:40 AM
$TTOO IMO seeing the Beckman Coulter / Innovaccer (AI) partnership is not an acquisition saves Danaher from reaching into its' dry powder....hmmm 🤔 Rainer Blair’s comments at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, Danaher CEO Rainer Blair provided a critical update on Cepheid’s trajectory strategy for Danaher, even while they digest the Masimo acquisition. The key takeaway is the sheer scale of their remaining "dry powder"—Blair’s confirmation of $20 billion+ Just saying glad Danaher is not depleting its dry powder to get into an AI partnership...
0 · Reply
Vince_2026
Vince_2026 Mar. 11 at 1:24 AM
$TTOO In 2019, Dr. Christopher Seymour and his team at the University of Pittsburgh published a landmark study in JAMA that challenged the "one-size-fits-all" approach to sepsis. By applying machine learning to the health records of over 60,000 patients, they discovered that sepsis isn't just one condition, but rather four distinct clinical "clusters" or phenotypes. Each phenotype represents a different way the body reacts to infection, which directly impacts which treatments will work and the patient’s likelihood of survival. day 2 speaker...
1 · Reply
Vince_2026
Vince_2026 Mar. 11 at 12:45 AM
$TTOO AI info DD req'd. Last speaker of day 2 Sepsis Alliance Symposium Christopher W. Seymour, MD, Professor at the University of Pittsburgh and a leading figure in sepsis research, has recently focused his R&D efforts on the clinical integration of T2 Magnetic Resonance (T2MR) technology to enable precision medicine in sepsis management. His most recent work (2024–2026) centers on validating how rapid, culture-independent diagnostics can shift the treatment paradigm from "one-size-fits-all" empiric therapy to targeted, phenotype-specific care. Key Recent R&D and Clinical Trials Dr. Seymour is a prominent investigator in major trials evaluating the T2Bacteria® Panel, which utilizes T2MR technology to detect pathogens directly from whole blood without the need for traditional blood cultures. Direct-from-blood Randomized Trial (2025–2026): see cont.
1 · Reply
Fair_Trader42
Fair_Trader42 Mar. 11 at 12:08 AM
$TTOO Lets ask "AI" if Doctors will trust an AI algorithm to administer Sepsis care? Must read: https://chatgpt.com/c/69b0b0df-5b04-832d-989b-025271757596
1 · Reply
LicketySplitz03
LicketySplitz03 Mar. 10 at 11:41 PM
$TTOO https://www.linkedin.com/posts/announcement-beckman-coulter-diagnostics-ugcPost-7436773306738827264-JQjj?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAEYxpb4Bm1Ed1IOOY8fbukunVJhWnTe2X9I&utm_campaign=share_via
1 · Reply
LicketySplitz03
LicketySplitz03 Mar. 10 at 11:36 PM
$TTOO https://www.linkedin.com/posts/utilizing-diagnostics-to-combat-infectious-ugcPost-7436753960847347712-yYHw?utm_source=share&utm_medium=member_ios&rcm=ACoAAEYxpb4Bm1Ed1IOOY8fbukunVJhWnTe2X9I
0 · Reply
LicketySplitz03
LicketySplitz03 Mar. 10 at 11:33 PM
$TTOO 👀⏰ https://www.linkedin.com/posts/vincent-zucconi-27978347_agilent-technologies-just-dropped-a-share-7437060604923691008-Ogu3?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAEYxpb4Bm1Ed1IOOY8fbukunVJhWnTe2X9I&utm_campaign=share_via
1 · Reply
LicketySplitz03
LicketySplitz03 Mar. 10 at 11:29 PM
$TTOO https://webapp.spotme.com/login/eventspace/sepsis-alliance-symposium-diagnostics-and-diagnostic-stewardship-2026
0 · Reply
LicketySplitz03
LicketySplitz03 Mar. 10 at 11:27 PM
$TTOO 👀 https://webapp.spotme.com/login/eventspace/sepsis-alliance-symposium-diagnostics-and-diagnostic-stewardship-2026
0 · Reply
Vince_2026
Vince_2026 Mar. 10 at 10:40 PM
$TTOO Day One and Two speaker schedule and link to sign up for tomorrows Sepsis Symposium Weds and Thurs. https://webapp.spotme.com/login/eventspace/sepsis-alliance-symposium-diagnostics-and-diagnostic-stewardship-2026
0 · Reply
Zefram
Zefram Mar. 10 at 9:15 PM
$TTOO multi billion dollar companies.... one of you guys could drive uber for a year and buy out ttoo... LOL
0 · Reply
HighStreetHero
HighStreetHero Mar. 10 at 7:32 PM
$TTOO Just going to tap the sign.
0 · Reply
Fair_Trader42
Fair_Trader42 Mar. 10 at 4:24 PM
$TTOO fyi .. Danaher's Acquisition History, prefer generally All-Cash deals. Share swap to aquire is rare with Danaher, just 1 in 10...
1 · Reply